Next Article in Journal
Managing the Toxicities of the FEC-100 Followed by Docetaxel Regimen: The Price of Success
Previous Article in Journal
Predictors of Positive Radial Margin Status in a Population-Based Cohort of Patients with Rectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 2
10.3747/co.v15i2.251
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Malignant Mesothelioma: Canadian Perspective and Research Directions

by
C.W. Lee
1,*,
J. Martin
2,
R. MacRae
3,
M.S. Tsao
4,
E. Nguyen
5,
M. Johnston
6,
P. Baas
7,
S. Laurie
3,
R. Feld
4,
N. Murray
8 and
F.A. Shepherd
4
1
BC Cancer Agency–Fraser Valley Centre, Surrey, BC, Canada
2
Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
3
The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada
4
University Health Network–Princess Margaret Hospital, Toronto, ON, Canada
5
University of Toronto, Toronto, ON, Canada
6
QE II Health Sciences Centre, Halifax, NS, Canada
7
The Netherlands Cancer Institute, Amsterdam, The Netherlands
8
BC Cancer Agency–Vancouver Centre, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(2), 104-111; https://doi.org/10.3747/co.v15i2.251
Submission received: 5 January 2008 / Revised: 6 February 2008 / Accepted: 7 March 2008 / Published: 1 April 2008

Abstract

Since the 1960s, the incidence of malignant mesothelioma in Canada has increased dramatically because of work-related asbestos exposures. Treatment options are limited. Although chemotherapy is now an accepted standard in the management of advanced disease, uncertainty surrounds the roles of radical surgery and radiation. In March 2007, a symposium was held in Vancouver, B.C., to review the current approach to malignant mesothelioma in Canada and to discuss development of a national clinical research strategy.
Keywords: asbestos; chemotherapy; mesothelioma; pathology; radiology; radiotherapy; surgery asbestos; chemotherapy; mesothelioma; pathology; radiology; radiotherapy; surgery

Share and Cite

MDPI and ACS Style

Lee, C.W.; Martin, J.; MacRae, R.; Tsao, M.S.; Nguyen, E.; Johnston, M.; Baas, P.; Laurie, S.; Feld, R.; Murray, N.; et al. Malignant Mesothelioma: Canadian Perspective and Research Directions. Curr. Oncol. 2008, 15, 104-111. https://doi.org/10.3747/co.v15i2.251

AMA Style

Lee CW, Martin J, MacRae R, Tsao MS, Nguyen E, Johnston M, Baas P, Laurie S, Feld R, Murray N, et al. Malignant Mesothelioma: Canadian Perspective and Research Directions. Current Oncology. 2008; 15(2):104-111. https://doi.org/10.3747/co.v15i2.251

Chicago/Turabian Style

Lee, C.W., J. Martin, R. MacRae, M.S. Tsao, E. Nguyen, M. Johnston, P. Baas, S. Laurie, R. Feld, N. Murray, and et al. 2008. "Malignant Mesothelioma: Canadian Perspective and Research Directions" Current Oncology 15, no. 2: 104-111. https://doi.org/10.3747/co.v15i2.251

Article Metrics

Back to TopTop